Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Brain Research|March 7, 2002
Antisense oligonucleotides to N-methyl-D-aspartate receptor subunits attenuate formalin-induced nociception in the ratRus Yukhananov, Jane Guan, Gregory CrosbyScience Translational Medicine|September 10, 2010
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancerJeffrey J Wallin, Jane Guan, Wei Wei Prior, et al.Genes & Cancer|July 7, 2016
The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromataseKlaus P Hoeflich, Jane Guan, Kyle A Edgar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2012
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivoJeffrey J Wallin, Jane Guan, Wei Wei Prior, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2010
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical modelsCarol O'Brien, Jeffrey J Wallin, Deepak Sampath, et al.Journal of Paediatrics and Child Health|June 30, 2017
Maternal help-seeking for child developmental concerns: Associations with socio-demographic factorsValsamma Eapen, Amelia Walter, Jane Guan, et al.Plos One|May 10, 2012
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodesJeffrey J Wallin, Jane Guan, Kyle A Edgar, et al.Cell Chemical Biology|May 20, 2026
Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancersWei Zhou, Musaddeque Ahmed, Jane Guan, et al.Nature Communications|March 31, 2026
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancerJackson Liang, Christy Ong, Kareem Heslop, et al.Molecular Cancer Therapeutics|October 15, 2011
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathwayJeffrey J Wallin, Kyle A Edgar, Jane Guan, et al.Pageof 2